Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Touloukian, C. E.
Right arrow Articles by Restifo, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Touloukian, C. E.
Right arrow Articles by Restifo, N. P.
[Cancer Research 61, 8100-8104, November 15, 2001]
© 2001 American Association for Cancer Research


Advances in Brief

Mining the Melanosome for Tumor Vaccine Targets

P.polypeptide Is a Novel Tumor-associated Antigen

Christopher E. Touloukian, Wolfgang W. Leitner, Paul F. Robbins, Steven A. Rosenberg and Nicholas P. Restifo1

Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892

To identify novel, tumor-specific target antigens for vaccine development, we studied immune responses to P.polypeptide, an Mr 110,000 integral melanosomal membrane protein associated with the Prader-Willi syndrome. Together with expressed sequence tag (EST) and serial analyses of gene expression (SAGE) library analyses, reverse transcription-PCR and Northern blotting verified that P.polypeptide expression was limited to melanoma and melanocytes. A single dominant epitope corresponding to positions 427–435 (IMLCLIAAV) was identified using allele-specific epitope forecasting combined with work in HLA-A*0201/Kb transgenic mice. This epitope was then used to generate de novo human P.polypeptide-specific CD8+ T cells capable of recognizing P.polypeptide expressing human tumor cell lines in an HLA-A*0201-restricted fashion. Thus, P.polypeptide may be valuable in the creation of novel therapeutic anticancer vaccines.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
K.-i. Yasumoto, H. Watabe, J. C. Valencia, T. Kushimoto, T. Kobayashi, E. Appella, and V. J. Hearing
Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17): RAPID PROCESSING IN THE ENDOPLASMIC RETICULUM AND GLYCOSYLATION IN THE EARLY GOLGI COMPARTMENT
J. Biol. Chem., July 2, 2004; 279(27): 28330 - 28338.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.